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A b s t r a c t  
The aim of this study was to determine the effect of two coprocessed materials in presence and 
absence of superdisintegrant (kyron T314) in the preparation of mirtazapine orodispersible tablets. 
Mirtazapine solubility was increased by complexation with kleptose forming an inclusion complex in 
a ratio 1:1. Quality by Design (QbD) was incorporated to determine the material attributes and the 
critical quality attributes (CQAs). Box behnken design was applied to study the effect of three 
independent variables X1: amount of lufiflash, X2: amount of pearlitol flash and X3: % of kyron T314 
on two responses, Y1: dissolution after 1 minute and Y2: disintegration time. All formulated ODTs 
showed disintegration time less than 35 seconds and all formulations showed a notable increase in 
dissolution rate. Design space was determined from the overlay plot of different variables, X1 and X2 
and X3 at two levels of the superdisintegrant. The one with maximum predicted dissolution rate and 
minimum predicted disintegration time was a formulation containing ludiflash (X1)= 9.25 mg, pearlitol 
flash (X2= 50 mg) and kyron T314= 3%. This formulation (Test ODT) was prepared and was 
subjected to in vivo study. Mirtazapine in human plasma was determined by LC-MS/MS and 
different pharmacokinetic parameters was determined for both test ODT and conventional oral tablet 
(Remeron). The pharmacokinetic parameters indicated that the two formulations are bioequivalence. 
Keywords: mirtazapine; Box-Behnken; ludiflash; pearlitol flash; kleptose HPB. 
 
Introduction 
One of the most popular problems that a patient may face during 
medication is 'dysphagia' or difficulty in swallowing,especially in 
elderly and pediatrics [1]. To solve this problem, pharmaceutical 
technologists have devoted considerableefforts for developing a 
novel type of dosage form fororal administration known as orally 
disintegrating tablets(ODTs) [2,3].These tablets cause 
instantaneous disintegration after putting on tongue, thereby 
releasing the drug quickly when come in contact with the saliva 
[4].This type of property in dosage form can be attained by addition 
of different varieties of excipients [5].These excipients need to have 
better flow, low/no moisture sensitivity, superior compressibility and 
rapid disintegration ability [6]. One such approach for improving the 
functionality of excipients is co-processing of two or more 
excipients.Coprocessing is based on the novel concept of two or 
more excipients interacting at the sub particle level, the objective of 
which is to provide a synergy of functionality improvement as well 
as masking the undesirable properties of individual [7] and lead to 
formulations with superior properties, likeimproved flow properties, 
improved compressibility, better dilution potential, fill weight 
uniformity, and reduced lubricant sensitivity [8].Ludiflash is 
acoprocessed material consisting of 90% mannitol, 5% Kollidon® 
CL-SF (crospovidone) and 5% Kollicoat SR 30 D (polyvinyl 
acetate).Itsone of the novel excipients for fast dissolving drug 
delivery which disintegrates rapidly within seconds with soft, 
creamy consistency. Ludiflash decreases the cost because it acts 
as all-in-one systemlike filler, binder and disintegrant and it givesa 
faster product development [9]. Pearlitol flash is a new generation 
of coprocessedmannitol-based excipients for formulation. A  
combination ofmannitol and starch,both of which are 
pharmacopoeia-compliant [10,11]. Thus, the effect of such 
coprocessed materials on the drug release from oral disintegrating 
tablets even in absence of superdisintegrant was worth studying. 
The model drug mirtazapine is a noradrenergic and specific 
serotonergic antidepressant (NaSSA) that acts by antagonizing the 
adrenergic alpha 2-autoreceptors and alpha2-heteroreceptors as 
well as by blocking 5-HT2 and 5-HT3 receptors [12].  The aim of 
this work is to study the effect of the two coprcessed materials, 
ludiflash and pearlitol flash on the release of mirtazapine from 
ODTs in presence and absence of superdisintegrant, kyron T314. 
The study was done by incorporation of a pharmaceutical 
development process named Quality by Design (QbD). QbD is 
concerned with the achievement of certain predictable quality with 
desired and predetermined specifications through relating the 
critical material attributes and critical process parameters (CPP) to 
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Materials and Methods 
Materials 
Mirtazapine was obtained from AUG Pharma, Egypt. Ludiflash was 
obtained from BASF, the chemical company, Germany. Pearlitol 
flash and kleptose HPB from Roqutte, France.Kyron T314 was 
obtained from Corel PharmaChem, India. Magnesium stearate 
from Egyptian International Pharmaceutical Co. EIPICO. Methanol 
HPLC Grade (Scharlau, spain). Diethyl ether (MTEDA, 
USA).Ammonium Formate of Reagent Grade (Sigma-Aldrich, 
Germany).Formic acid of Reagent Grade (Sigma-Aldrich, 
Germany).n-Hexane 95%(Alliance Bio, U.S.A). 
Methods 
Phase solubility studies for mirtazapine in kleptose 
HPB. 
Phase solubility studies were carried out according to the method 
reported by Higuchi and Connors. An excess amount of 
mirtazapine was added to the aqueous solution of kleptose solution 
(molecular weight =1400) at various concentrations (0.002-
0.01M).The contents were stirred for 72 h at37μ0.5ÀC.After 
equilibrium, the samples were filtered through 0.45 μm Millipore 
membrane filtersand absorbance recorded using UV/Vis 
spectrophotometer (UV-1700 Schimadzu spectrophotometer, 
Tokyo, Japan) at 292 nm [15]. 
The apparent stability constant was calculated from the initial 





Preparation of cyclodextrininclusion complexes 
Preparation of cogrindingformulations (CG) 
For co-grinding formulations, mirtazapine with kleptose were mixed 
inthreegeomatrix ratios(1:0.5, 1:1 and 1:2) and triturated in glass 
mortar pestle for 20 minutes and passed through 80 mesh screen 
[16]. 
Characterization of inclusion complex 
Differential scanning calorimetry (DSC) 
Thermal behavior of mirtazapine, kleptoseand inclusion complex 
were examined using thermalanalyzer(Differential scanning 
calorimeter, model Mettler DSC60, Switzerland).The sample size 
was 5 mg and thetemperature range was between 30 and 300 
ÀC.Nitrogen was used as carrier gas and DSC analysiswas 
performed at heating rate of 10ÀC/min. 
Fourier transfer Infrared spectroscopy (FTIR) 
Infrared spectra of pure mirtazapine, kleptose and inclusion 
compelx were recorded by KBr method usingpyeUnicam SP 
1000 IR Spectrophotometer, type pw3710, Holland. Scanning was 
done from 750 -4000 cm-1. 
In vitro dissolution studies of mirtazapine inclusion 
complexes 
Dissolution of mirtazapine (10 mg) and its inclusion complexes 
equivalent to 10 mg of mirtazapine was studied using a dissolution 
apparatus with paddles rotating at 75 rpm.The dissolution was 
performed in 300 mL of phosphate buffer (pH 6.8) at 37 μ 0.5ĈC.At 
fixed time intervals, samples were withdrawn, filtered, and 
spectrophotometrically assayed for drug content at 292 nm.  
Determination of Quality Target Product Profile (QTPP) 
The Target Product Quality Profile (TPQP) is a term that is a 
natural extension of Target product Profile (TPP) for product 
quality. It is the quality characteristics that the drug product should 
possess in order to reproducibly deliver the therapeutic benefit 
promised in the label. The TPQP guides formulation scientists to 
establish formulation strategies and keep formulation efforts 
focused and efficient. The target product intended to be formulated 
in this work is an orodispersible tablets containing 10 mg 
mirtazapine. Tablets were formulated to give complete drug 
release within few minutes. Mirtazapine release was increased by 
complex formation with kleptose HPB.  
Determination of Material Attributes of excipients and 
Drug Product CQAs  
Material attributes excepients used in the formulation of 
mirtazapine orodispersible tablets were two coprocessed materials 
- ludiflash and pearlitol flash- and one super disintegrant (kyron 
T314). Ludiflash is composed of 90 % mannitol which is a fast 
dissolving filler with a mildly sweet taste, 5 % kollidon® CL-SF, a 
superior tablet disintegrant and 5 % kollicoat® SR 30D, a 
hydrophobic binder for enhanced disintegration. Perlitol flash is a 
compound of mannitol and starch designed for oral disintegrating 
tablets. Kyron T-314 is derived from crosslinked polymer of 
polycarboxylic acids as per USP/NF & has the K+ ionic form. It is a 
very high purity polymer used in pharmaceutical formulations as a 
superfast disintegrant as well as dissolution improver in solid 
dosage forms [17]. CQAs of solid oral dosage forms are typically 
those aspects affecting product purity, strength, drug release and 
stability, to achieve this, the percent of drug released after 1 minute 
and tablet disintegration time were determined to ensure the 
desired product quality.  
Application of Box Behnkendesign for determiningthe 
effect of different variables. 
Box-Behnken design was applied using three factors and three 
levels which required 13 experiments.The three factors are 
X1:amount of ludiflash, X2:amount of pearlitol flash and X3, 
percentage of superdisintegrant (kyron T314) and are represented 
by ă1, 0 and +1, analogous to the low, middle and high values 
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respectively.  A condition for the Box-Behnken design is that these 
levels be equally spaced to insure orthogonality (Table 1). 





whereYis the response, Xthe factors and b the coefficients of each 
term calculated by multiple regression analysis. The responses 
studied were Y1the percent of drug released after 1 minute and Y2 
is the disintegration time of the tablets. 
 
Table 1.Experimental domains and coding of the variables 
Variables                       Levels 
               -1  0  +1 
Material attributes (process inputs) 
Amount of ludiflash (X1)                          0 25 50
Amount of pearlitol flash (X2)                             0  25  50 
Percentage of kyron T314 (X3)             0   3  6  
Responses (CQAs) 
Y1 Drug released after 1 minute. 
Y2 Disintegration time of the tablets. 
 
Preparationof  mirtazapineorodispersible tablets 
Mirtazapine-kleptose complexes were formulated into 
orodispersible tablets by direct compression method containing 
drug equivalent to 15mg mirtazapine. All ingredients were properly 
mixed togetherthen compressed in to tablet by using rotary single 
punch tablet machine. Different formulations of mirtazapine 
orodispersible tabletsare shown in Table 2.  
 
Table 2.Formulae of orodispersible mirtazapine tablets obtained from Box-Behnken design. 
 
Evaluation of mirtazapine ODT 
The prepared tablets were evaluated for weight variation, 
hardnessand % friability. For weight variation, 20 tablets were 
selected at random and an average weight was determined using 
Electronic Balance. The hardness of 6 tablets was determined 
using the Monsanto hardness tester. Friability was determined by 
first weighing 10 tablets after dusting and placing them in a friability 
tester (Roche friabilator), which was rotated for 4 min at 25 rpm. 
After dusting, the total remaining mass of tablet was recorded and 
the percent friability was calculated [18]. 
In vitro disintegration time 
The disintegration time for all formulations was carried out 
usingtablet disintegration test apparatus. Six tablets were 
placedindividually in each tube of disintegration test apparatus and 
discswere placed. The water was maintained at a temperature of 
37Ĉ μ2ĈC and time taken for the entire tablet to disintegrate 
completelywas noted [18]. 
Water absorption ratio 
A piece of tissue paper folded twice was placed in a small Petri 
dish (internal diameter = 6.5cm) containing 5 ml of distilled water. A 
tablet was placed on the tissue paper. The wetted tablet was 
weighed. The test was done in triplicate. The water absorption 
ratio(R) was determined according to the following equation  
Water absorption ratio ሺܴሻ ൌ ௐ௔ିௐ௕
ௐ௕
X 100 
Where, ܹܽ is the weight of the tablet before the test and ܹܾis 
the weight of the tablet after water absorption [19]. 
In vitro dissolution study of tablets for ODTs 
In-vitro dissolution of mirtazapine ODT was studied using a 
dissolution apparatus with paddles rotating at 75 rpm. The 
Ingredients  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13
Drug:complex 94 94 94 94 94 94 94 94 94 94 94 94 94
Ludiflash 0 25 50 25 25 25 50 0 50 50 0 25 0
Pearlitol 50 25 50 50 50 0 0 25 25 25 25 0 0
Kyron T314 6.6 6.6 6.6 0 13.2 0 6.6 0 13.2 0 13.2 13.2 6.6
Mag. St. 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2
Avicel 102 to  220 220 220 220 220 220 220 220 220 220 220 220 220
Darwish et al. International Journal of Drug Delivery 5 (3) 309-322 [2013] 
 
PAGE | 312 |
 
 
dissolution was performed in 300 mL of phosphate buffer (pH 6.8) 
at 37 μ 0.5ĈC. At fixed time intervals, samples were withdrawn, 
filtered, and spectrophotometrically assayed for drug content at 
292 nm. Percent drug released after 20 minutes was determined. 
Determination of design space and defining control 
strategy 
The relationship between the process inputs (material attributes 
XÊs) and the critical quality attributes (YÊs) can be described in the 
design space [13]. Working within the design space is not 
considered as a change. Movement outside of the Design space is 
considered to be a change and would normally initiate a regulatory 
post approval change.Control strategy is defined as „a planned set 
of controls, derived from current product and process 
understanding that assures process performance and product 
quality‰. The control strategy in the QbD paradigm is established 
via risk assessment that takes into account the criticality of the 
CQA and process capability [20]. 
In vivo Study 
Six healthy, preferably non-smoking, volunteers, 18-56 years 
ofage, and within 10% of ideal body weight for height and build, 
were subjected to single-dose fasting two-ways crossover 
bioequivalence study with a washout period of seven days.Each 
volunteer received a single oral dose of test and reference 
products of mirtazapine as follows; one oral disintegrated tablet of 
test product (ODT) of 15mg dose and half scored tablet of 
reference product of 30mg (Remeron®, N.V.Organon, the 
Netherlands) which is equivalent to 15 mg mirtazapine. The orally 
disintegrated tablets were orally administered under low light 
condition during each period of the study under the supervision of a 
trained Medical Officer. Subjects were instructed to let the tablets 
completely dissolve on the tongue before swallowing the saliva and 
then, 240ml of water was administered 30 seconds after drug 
administration. 
The study protocol, which complied with the  recommendations of 
the Helsinki Declaration, was fully  approved  and performed by 
Drug Research Centre (DRC, a certified center  that performs 
bioequivalence studies and biowaiver studies based on Central 
Administration for Pharmaceutical Affairs CAPA guidelines & 
international regulations on Good Clinical Practice provided by 
benchmark regulatory bodies like World Health organization 
(WHO), U.S Food & Drug Administration (FDA), EMEA (European 
Agency for the Evaluation of Medicinal Products) and ICH 
(International Conference of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use).  
Blood samples were taken at a frequency sufficient for assessing 
Cmax, AUC and other parameters. Sampling time of both test and 
reference tablets was at 0 (pre-dose), 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 
2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hours. Blood 
samples were collected in heparinized tubes, centrifuged and 
separated plasma was aspirated and transferred into plastic tubes 
and were stored at î20ĈC until assayed.Different parameters were 
measured such as the area under the plasma/blood concentration-
time curve truncated from time (zero) to time (72) (AUC0-72t), area 
under the plasma/blood concentration-time curve from time (zero) 
to time (infinity) (AUC0-infinity), and time to half drug concentration 
(tó). Peak drug concentration (Cmax) and the time to peak drug 
concentration (Tmax), obtained directly from the data without 
interpolation. 
The assay of mirtazipine in plasma was performed using Liquid 
chromatography (Agilent 1200 series, USA) coupled with mass 
spectrometry detection (Agilent 1200 series Triple Quad, USA) 
operated in positive electrospray ionization mode (ESI). Thermo, 
Hypersil Gold C8, 4.6 x 50 mm, 5.0 micron analytical column was 
used and a mobile phase consists of Methanol:AmmFormate 
pH3.5 (95:5) v/v and a flow rate of 0.6 
ml/min.QuetiapineFumaratewas used as an internal standard. 
Before assay, the linearity, the precision, the accuracy and the 
selectivity of the method were demonstrated.The Procedure of 
calculation of mirtazapine in volunteers' human plasma was 
performed automatically by using Mass Hunter software Program 
of LC-MS/MS instrument. 
Results and Discusion 
Phase solubility studies 
Phase solubility diagram can be classified as ALtype according to 
Higuchi and Connors as shown in Figure 1. It's clear that the 
solubility of mirtazapine linearly increased with increasing 
concentration of kleptose (0.002 M-0.01 M). From the straight line, 
it was concluded that the increase in solubility was due to formation 
of 1:1 complex. The solubility constant (Kc) was calculated from 
the slope of the straight line according to equation, 
K1:1 = Slope/Intercept (1 - Slope)  
The stability constant was found to be 672.72M-1, which is 
adequate for complex formation. 
The phase solubility diagram shows an ALtype. The linear 
mirtazapine-kleptose curve suggested the formation of 1:1 
inclusion complex which resulted from molecular interactions 
between mirtazapine and kleptose.  
 
Figure.1. Phase solubility plot of mirtazapine and kleptose. 
Darwish et al. International Journal of Drug Delivery 5 (3) 309-322 [2013] 
 




Characterization of inclusion complex 
Differential scanning calorimetry (DSC) 
DSC was carried out to identify the inclusion complex between the 
drug and kleptose.Figure (2) shows the DSC thermograms for 
mirtazapine, kleptose and 1:1 inclusion complex. Endothermic 
peak of mirtazapine appeared at 118 ĈC, which corresponds to its 
melting point, while kleptose shows a broad endothermic peak at 
98.04 ĈC. The intensity of the peak of the drug in the inclusion 
complex was clearly decreased while that of kleptose was shifted 
and appeared at 82.67 ĈC. DSC thermogram of mirtazapine-
kleptose inclusion complex shows the disappearance or shifting of 
endothermic peaks of drug. This is mostly an indication of 
formation of an inclusion complex resulted from entrapment of 
mirtazapine in the kleptose cavity [21].   
 
 
Figure.2. DSC thermogram of (a) mirtazapine, (b) kleptose and (c) 
inclusion complex 
Fourier transfer Infrared spectroscopy (FTIR) 
IR spectroscopy of mirtazapine (Figure 3a) shows C-H stretching 
vibrations band of methyl group at 2931 cm-1. Methyl group 
attached to a N2 atom gives rise to a band at 2854 cm-1 (22). 
Bands for C-C stretching of the phenyl group appeared at 1585 cm-
1 and 1444 cm-1. The primary aromatic amines with N directly on 
the ring give bands at 1336-1200 cm-1. The benzene ring C-H 
appears in the range of 1359-1074 cm-1 and 788-636 cm-1 for the 
in plane and out of plane bending vibrations respectively (23&24). 
The IR spectroscopy of kleptose (Fig. 3b) is characterized by large 
peaks at 3408 cm-1 characterized for O-H, 2926 cm-1 for C-H, 1647 
cm-1 for H-O-H bending and 1029 cm-1 for C-O-C. Figure 3c shows 
the IR spectrum for the inclusion complex. The broad peak for O-H 
group appeared in the inclusion complex. All drug peaks were 
smoothed and the peak at 1647 cm-1 in kleptose was disappeared. 
IR spectroscopy for the inclusion complex shows a strong physical 
interaction between the pure mirtazapine and kleptose and was 
illustrated by the smoothness of all drug peaks. Another proof for 
the interaction was seen by the disappearance of the peak at 1647 
cm-1 in kleptose (for water of crystallization) which means that 
mirtazapine replaces water in the cyclodextrin cavity of  kleptose. 
The overall interaction is said to be noncovalent as no new peaks 
were seen in the inclusion complex [25]. This could be explained 
on the basis of the ability of  cyclodextrin- drug complex to modify 
the physicochemical properties of drugs such as crystal habit and 
solubility and thereby forming a highly water soluble amorphous 
forms [26]. Kleptose which is hydroxypropylbetacyclodextrins are 
purified polydisperse products resulting from the controlled reaction 
of propylene oxide and native betacyclodextrin [27]. 
 
Figure.3. FT-IR spectra of a: pure mirtazapine, b: kleptose HPB and c: inclusion complex 
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In-vitro dissolution of mirtazapine inclusion complex 
Figure 4 shows the dissolution profile of pure mirtazapine and it's 
inclusion complexes. It was found that only 19.21% of pure 
mirtazapine was released after 20 minutes while a complete drug 
release was obtained from the inclusion complex (ratio 1:1) after 
the same period. Figure (4) also shows that mirtazapine inclusion 
complex ratio 1:1 gave highest drug release in comparison with the 
other two ratios 1:0.5 and 1:2.   
 
Figure.4. % Drug released from pure mirtazapine (PD) and from 
coground (CG) inclusion complexes in different ratios. 
Evaluation of mirtazapine ODTs 
The drug content was found to be from 98.10+0.51 to 
101.01+0.43as shown in Table 3. The results were within the range 
that indicated uniformity of mixing of the drug with excipients in the 
developed formulations. Friability of all formulation was in the 
range of from 0.58+0.05 to 0.89+0.02 % which was found to be 
within the approved range (<1%) in all formulations. The hardness 
of the tablets was found in the range of 3.01+0.30 to 4.61+0.62 
kg/cm2. The average percentage weight variation was found within 
the pharmacopoeial limits of μ10%. The obtained results were 
found to be from 218.3+1.52 to 221.9+2.08. 
In vitro disintegration time 
The disintegration time recorded for all the formulation was found 
in the range of 10μ0.60 to 33μ0.70 seconds. All the formulations 
were disintegrated in less than 35 seconds. The results are shown 
in Table 3.  
Water absorption ratio 
Formulation containing both pearlitol flash and ludiflash in addition 
to kyron T314 showed highest water absorption ratio ( F3: 
85.3+0.51 %). Minimum water absorption ratio was seen in 
formulation F13 which deprived from both pearlitol flash and 
ludiflash (Table 3). 
 


















































F1 99.45+0 .43 0.73+0.03 3.49+0.36 219.4+1.59 74.0+0.52 62.5+0.62 28+0.57
F2 98.54+0.50 0.77+0.03 3.88+0.49 221.9+2.08 67.1+1.0 59.9+0.51 12+0.76
F3 100.2+0.50 0.89+0.02 3.29+0.31 220.1+1.56 85.3+0.51 66.1+0.72 10+0.60
F4 99.77+0.57 0.83+0.03 4.61+0.62 220.9+1.59 81.5+0.76 63.3+0.66 16+0.76
F5 98.10+0.51 0.69+0.02 3.96+0.33 218.3+1.52 82.4+0.45 56.4+0.51 22+1.50
F6 101.01+0.43 0.87+0.01 4.11+0.51 220.4+2.07 51.9+0.70 48.6+0.82 31+0.61
F7 100.91+0.50 0.81+0.04 4.15+0.61 221.8+1.91 58.5+0.90 53.8+0.42 29+0.72
F8 99.19+0.49 0.87+0.03 3.93+0.41 219.8+2.04 63.4+0.51 49.9+0.70 31+0.51
F9 100.73+0.43 0.85+0.04 3.25+0.56 221.5+2.01 77.9+0.55 48.2+0.66 20+0.80
F10 98.27+0.50 0.78+0.03 3.08+0.44 219.0+1.82 76.8+0.52 49.1+0.64 25+0.50
F11 99.74+0.50 0.72+0.03 4.09+0.38 221.8+1.62 70.8+0.51 39.5+0.72 33+0.70
F12 99.31+0.43 0.58+0.05 3.12+0.53 221.4+1.90 53.4+0.50 43.3+0.91 28+0.73
F13 100.08+0.50 0.77+0.04 3.01+0.30 220.0+1.72 49.3+0.41 48.2+0.55 31+0.65
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In vitro dissolution study of mirtazapine ODTs 
Figure 5 shows the percent drug released from different 
formulations. It is clear that the presence of the two coprocessed 
material resulted in a notable increase in mirtazapine release even 
in absence of the superdisintegrant. Formulation F2 gave complete 
drug release within 15 minutes. Presence of kyron T314 in 
concentration 3% gave higher drug release than 6%.  
 
 
Figure.5. % Drug released from different mirtazapine formulations, a: formulations from 1-7 and b: formulations from 8-13.
 
 
In vitro drug release from inclusion complex shows a complete 
mirtazapine release within 20 minutes due to high water solubility 
of kleptose. Mirtazapine orodispersible tablets containing pearlitol 
flash showed high water absorption ratio due to starch 
hydrophilicity that gives good wettability properties. In case of 
formulations with ludiflash, the high retention capacity of water was 
due to kollidon® CL-SF with very small particles and high 
absorption rate. Incorporation of two coprocessed materials led to 
a notable increase in water absorption rate which was reflected on 
a rapid disintegration time. Kyron T314 breaks the tablets into very 
smaller particles, thus it increases the effective surface area for the 
absorption of the active substances and thus it decreases the 
disintegration time and then the dissolution [28]. 
Experimental design 
Box Behnken design was applied and the material attributes were 
determined to be amount of ludiflash (X1), amount of pearlitol (X2) 
and percentage of kyron (X3). The CQAs were drug released after 
minute (Y1) and disintegration time of the tablets (Y2). The material 
attributes and response variables were studied and related to 
determine the effect of each factor on the determined responces 
using Design Expert-8 [29]. 
Results shows that the percent drug released after one minute (Y1) 
ranged from 39.5% in F2 to 66% in F7. The polynomial equation 
obtained for this response was: 
Y1 (dissolution after 1 minute) = 60.00 + 2.18 A + 6.83 B - 2.88 C ă 
0.45 AB + 2.35 AC - 0.40 BC - 4.28 A2 + 1.72 B2 ă 9.12 C2.  
The range of responses for Y2 was found to be 10 seconds in F3 to 
33 seconds in F6. The polynomial equation obtained for this 
response was: 
Y2 (disintegration time) = 11.88 ă 4.88 A ă 5.37 B + C ă 4 AB ă 
1.74 AC + 2.25 BC +7.81 A2 + 4.81 B2 + 7.56 C2. 
The equations represent the quantitative effect of process variables 
(X1, X2, and X3) and their interactions on the responses (Y1 and 
Y2). The values of X1, X2, and X3 were substituted in the equation 
to obtain the theoretical values of Y1 and Y2. 
Based on the experimental design and factor combination, a 
quadratic model was found to be significant for percent drug 
released after 1 minute (X1)with F value of 235.76 and P value < 
0.0001 and for tablet disintegration time (X2) with F value of 155.50 
and P value < 0.0001. 
Table (4) shows the analysis of variance for the first response (Y1: 
percent drug released after 1 minute). This model shows a 
nonsignificant lack of fit of value = 0.84. It also shows the analysis 
of variance for the second response (Y2: disintegration time). This 
model shows a nonsignificant lack of fit of F value = 5.72. It can be 
concluded that all factors A (amount of ludiflash), B (amount of 
pearlitol) and C (percent of disintegrant) significantly affected the 
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Table  4. Analysis of variance for Y1 (dissolution after 1 minute) and for Y2 (disintegration time). 
Source Sum of Squares Mean Square F value p-value Prob>F 
Model (Y1) 950.29 105.59 235.76 < 0.0001 
A 37.85 37.85 84.50 < 0.0001 
B 372.65 372.65 832.06 < 0.0001 
C 66.13 66.13 147.65 < 0.0001 
AC 0.81 0.81 1.81 0.2206 
BC 22.09 22.09 49.32 0.0002 
AB 0.64 0.64 1.43 0.2708 
A2 76.95 76.95 171.82 < 0.0001 
B2 12.53 12.53 27.98 0.0011 
C2 350.59 350.59 782.82 < 0.0001 
Model (Y2) 1424.73 158.30 216.94 < 0.0001 
A 144.50 44.50 198.02 < 0.0001 
B 364.50 364.50 499.51 < 0.0001 
C 4.50 4.50 6.17 0.0420 
AC 90.25 90.25 123.68 < 0.0001 
BC 20.25 20.25 27.75 0.0012 
AB 42.25 42.25 57.90 0.0001 
A2 232.75 232.75 318.97 < 0.0001 
B2 148.31 148.31 203.25 < 0.0001 
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Figure.6. Response surface plots (contour and 3D) showing the 
effect of different independent variable (X1: ludiflash amount, X2: 
pearlitol flash amount and X3: kyron T314 percent) on Y1: 
dissolution after 1 minute.  
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Figure.7. Response surface plots (contour and 3D) showing the 
effect of different independent variable (X1: ludiflash amount, X2: 
pearlitol flash amount and X3: kyron T314 percent) on Y2: 
disintegration time. 
 
The relationship between the dependent and independent 
variables were further elucidated using contour plots and response 
surface plots. Figure (6) shows the response plots (3D) and the 
contour plots for the effect of factors X1, X2, and X3 on the first 
response Y1. It was observed that increasing the amout of ludiflash 
and pearlitol flash increases the dissoltion, being more clear in 
case of pearlitol flash. Increasing the percent of kyron till 3% 
increases the dissolution to a certain limit, after which dissolution 
started to decrease. Regarding the second response 
(disintegration time), increasing the amount of all factors decreases 
the disintegration time and after reaching certain values, increasing 
thses factors, lead to an increase in the disintegration time as 
shown in Figure (7). 
Determination of design space and control strategy 
With multiple responses one need to find regions where 
requirements simultaneously meet the critical properties (the sweet 
spot). By superimposing or overlaying critical response contours on 
a contour plot, one can visually search for the best compromise. In 
other words, design space can be determined from the common 
region of successful operating ranges for multiple CQAs. Figure (8) 
shows the determined design space composing of the overlapping 
region of different ranges of the CQAs in two conditions, kyron 
T314 (3%) and in absence of superdisintegrant (zero %). In the first 
condition as seen in the Figure, the two optimum values for 
ludiflash and pearlitol flash were given and they were (X1=9.25 mg, 
X2=50 mg) and (X1=36.67 mg, X2=5.36 mg). For the second 
condition, the absence of superdisintegrant gave rise to two 
optimum values and they were, (X1=16 mg, X2=50 mg) and (X1=50 
mg, X2=50 mg). Among all mentioned values, the one with 
maximum predicted dissolution rate and minimum predicted 
disintegration time was a formulation containing ludiflash (X1)= 
9.25 mg, pearlitol flash (X2= 50 mg) and kyron T314= 3%. This 
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Table 5. Mean pharmacokinetic parameters for mirtazapinein ODT 
and conventional oral tablets administered to six healthy volunteers 
 
Conclusion 
In this study, mirtazapine solubility was increased by complexation 
with kleptose HPB, then  orodispersible tablets were prepared 
using two different coprocessed materials, ludiflash and pearlitol 
flash. Box-Behnken design was used to investigate the influence of 
different formulation variables on the prepared tablets.Mirtazapine 
in human plasma was determined by LC-MS/MS and different 
pharmacokinetic parameters was determined for both test ODT 
and conventional oral tablet (Romeron). The pharmacokinetic 
parameters indicated that the two formulations are bioequivalence. 
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